Immuno-oncology company, Imugene (ASX:IMU) has announced the Phase 1b clinical trial of its cancer vaccine (HER-Vaxx) for gastric cancer patients has completed recruitment.
The ongoing Phase 1b lead-in trial is testing three different doses of the vaccine in combination with the current standard of care chemotherapy.
The company says completion of recruitment is an important milestone for the study, and, the many medical professionals seeking treatments for patients with advanced gastric cancer who often have very few medical options.
Imugene is conducting trials in Asia and Eastern Europe where clinicians and patients have difficulty accessing expensive antibody treatments.
Shares in Imugene (ASX:IMU) are trading is trading 4.55 per cent higher to 2 cents.